1
|
Kamal MA, Farahat RA, Awad AK, Tabassum S, Labieb F, Bejan CA, Al-Tawfiq JA, Dhama K, Dergaa I. Global trends of monkeypox-related articles: A bibliometric analysis over the last five decades (1964 - July 14, 2022). J Infect Public Health 2023; 16:1333-1340. [PMID: 37429097 PMCID: PMC10236922 DOI: 10.1016/j.jiph.2023.05.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 05/14/2023] [Accepted: 05/28/2023] [Indexed: 07/12/2023] Open
Abstract
BACKGROUND The first human monkeypox (MPX) case was identified in the Democratic Republic of Congo (DRC) in 1970 with an outbreak in 2010 and the first human MPX case in the UK in 2022. In this study, we conducted a bibliometric analysis of the literature on monkeypox based on the Web of Science Core Collection (WOSCC) of the Institute for Scientific Information (ISI) to identify relevant topics and trends in monkeypox research. METHODS We searched the Web of Science from 1964 until July 14, 2022, for all publications using the keywords "Monkeypox" and "Monkeypox virus." Results were compared using numerous bibliometric methodologies and stratified by journal, author, year, institution, and country-specific metrics. RESULTS Out of 1170 publications initially selected, 1163 entered our analysis, with 65.26 % (n = 759) being original research articles and 9.37 % (n = 109) being review articles. Most MPX publications were in 2010, with 6.02 % (n = 70), followed by 2009 and 2022 at 5.67 % (n = 66) each. The USA was the country with the highest number of publications, with n = 662 (56.92 %) of total publications, followed by Germany with n = 82 (7.05 %), the UK with n = 74 (6.36 %), and Congo with n = 65 (5.59 %). Journal of Virology published the highest number of MPX publications, followed by Virology Journal and Emerging Infectious Diseases with n = 52 (9.25 %), n = 43 (7.65 %), and n = 32 (5.69 %) publications, respectively. The top contributing institutions were the Centers for Disease Control and Prevention (CDC), the US Army Medical Research Institute of Infectious Diseases, and the National Institutes of Health (NIH)National Institute of Allergy and Infectious Diseases (NIAID). CONCLUSION Our analysis provides an objective and robust overview of the current literature on MPX and its global trends; this information could serve as a reference guide for those aiming to conduct further MPX-related research and as a source for those seeking information about MPX.
Collapse
Affiliation(s)
| | - Ramadan A Farahat
- Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh 33511, Egypt
| | - Ahmed K Awad
- Faculty of Medicine, Ain-Shams University, Cairo, Egypt
| | | | - Fatma Labieb
- Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt
| | - Cosmin A Bejan
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Jaffar A Al-Tawfiq
- Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Izatnagar, Uttar Pradesh 243122, India
| | - Ismail Dergaa
- Primary Health Care Corporation (PHCC), Doha, Qatar; Research Unit Physical Activity, Sport, and Health, UR18JS01, National Observatory of Sport, Tunis 1003, Tunisia; High Institute of Sport and Physical Education, University of Sfax, Sfax, Tunisia.
| |
Collapse
|
2
|
Katamesh BE, Madany M, Labieb F, Abdelaal A. Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks? Expert Rev Vaccines 2023; 22:366-368. [PMID: 37017380 DOI: 10.1080/14760584.2023.2198600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2023]
Affiliation(s)
- Basant E Katamesh
- Tanta Research Team, El-Gharbia, Tanta, Egypt
- Faculty of Medicine, Tanta University Hospitals, El-Gharbia, Tanta, Egypt
| | - Maysa Madany
- Tanta Research Team, El-Gharbia, Tanta, Egypt
- Faculty of medicine, South Valley University, Qena, Egypt
| | - Fatma Labieb
- Tanta Research Team, El-Gharbia, Tanta, Egypt
- Faculty of medicine, Beni-Suef University, Beni-Suef, Egypt
| | - Abdelaziz Abdelaal
- Tanta Research Team, El-Gharbia, Tanta, Egypt
- Faculty of Medicine, Tanta University Hospitals, El-Gharbia, Tanta, Egypt
- Clinical Research Scholar, Harvard Medical School, Boston, MA, USA
- Master of Science in Clinical Investigations (MMSCI), Harvard Medical School, Boston, MA, USA
- Research Fellow, Doheny Eye Institute, University of California, Los Angeles CA, USA
| |
Collapse
|
3
|
Abuelazm M, Ghanem A, Awad AK, Farahat RA, Labieb F, Katamesh BE, Abdelazeem B. The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig 2022; 42:1031-1047. [PMID: 36315350 PMCID: PMC9628625 DOI: 10.1007/s40261-022-01213-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/09/2022] [Indexed: 12/03/2022]
Abstract
BACKGROUND AND OBJECTIVE Nitazoxanide, a US Food and Drug Administration-approved antiparasitic agent, was reported to be effective in treating coronavirus disease 2019 (COVID-19). The lack of effective and precise treatments for COVID-19 infection earlier in the pandemic forced us to depend on symptomatic, empirical, and supportive therapy, which overburdened intensive care units and exhausted hospital resources. Therefore, the aim of this systematic review and meta-analysis was to assess the efficacy and safety of nitazoxanide for COVID-19 treatment. METHODS A systematic review and meta-analysis synthesizing relevant randomized controlled trials from six databases (MedRxiv, WOS, SCOPUS, EMBASE, PubMed, and CENTRAL) until 17 May 2022 was conducted. Risk ratio (RR) for dichotomous outcomes was used and data with a 95% confidence interval (CI) are presented. The protocol was registered in PROSPERO with ID: CRD42022334658. RESULTS Six randomized controlled trials with 1412 patients were included in the analysis. Nitazoxanide was effective in accelerating viral clearance compared with placebo (RR: 1.30 with 95% CI 1.08, 1.56, p = 0.006) and reducing oxygen requirements (RR: 0.48 with 95% CI 0.39, 0.59, p = 0.00001), but we found no difference between nitazoxanide and placebo in improving clinical resolution (RR: 1.01 with 95% CI 0.94, 1.08, p = 0.88), reducing the mortality rate (RR: 0.88 with 95% CI 0.4, 1.91, p = 0.74), and intensive care unit admission (RR: 0.69 with 95% CI 0.43, 1.13, p = 0.14). Moreover, nitazoxanide was as safe as placebo (RR: 0.9 with 95% CI 0.72, 1.12, p = 0.34). CONCLUSIONS Compared with placebo, nitazoxanide was effective in expediting viral clearance and decreasing oxygen requirements. However, there was no difference between nitazoxanide and placebo regarding clinical response, all-cause mortality, and intensive care unit admission. Therefore, more large-scale studies are still needed to ascertain the clinical applicability of nitazoxanide in COVID-19.
Collapse
Affiliation(s)
| | - Ahmed Ghanem
- Cardiology Department, The Lundquist Institute, Torrance, CA, USA
| | - Ahmed K Awad
- Faculty of Medicine, Ain Shams University, Cairo, Egypt
| | | | - Fatma Labieb
- Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
| | | | - Basel Abdelazeem
- Department of Internal Medicine, McLaren Health Care, Flint, MI, USA
- Department of Internal Medicine, Michigan State University, East Lansing, MI, USA
| |
Collapse
|
4
|
Farahat RA, Sah R, El-Sakka AA, Benmelouka AY, Kundu M, Labieb F, Shaheen RS, Abdelaal A, Abdelazeem B, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Garout MA, León-Figueroa DA, Pachar M, Suárez JA, Ramirez JD, Paniz-Mondolfi A, Rabaan AA, Al-Tawfiq JA, Nishiura H, Ortiz-Martínez Y, Garcia-Robledo JE, Cimerman S, Barbosa AN, Pagliano P, Zambrano-Sanchez G, Cardona-Ospina JA, Bížová B, Rodriguez-Morales AJ. Human monkeypox disease (MPX). Infez Med 2022; 30:372-391. [PMID: 36148174 PMCID: PMC9448318 DOI: 10.53854/liim-3003-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 07/24/2022] [Indexed: 05/24/2023]
Abstract
Monkeypox is a rare viral infection, endemic in many central and western African countries. The last international outbreak of monkeypox reported outside Africa occurred back in 2003. However, monkeypox has reemerged at a global scale with numerous confirmed cases across the globe in 2022. The rapid spread of cases through different countries has raised serious concerns among public health officials worldwide prompting accelerated investigations aimed to identify the origins and cause of the rapid expansion of cases. The current situation is reminiscent of the very early stages of the still ongoing COVID-19 pandemic. Overlapping features between these, two seemingly alike viral entities include the possibility for airborne transmission and the currently unexplained and rapid spread across borders. Early recognition of cases and timely intervention of potential transmission chains are necessary to contain further outbreaks. Measures should include rapid and accurate diagnosis of cases meeting case definitions, active surveillance efforts, and appropriate containment of confirmed cases. Governments and health policymakers must apply lessons learned from previous outbreaks and start taking active steps toward limiting the recent global spread of monkeypox. Herein, we discuss the status of the current monkeypox outbreaks worldwide, the epidemiological and public health situation at a global scale and what can be done to keep at bay its further expansion and future global implications.
Collapse
Affiliation(s)
| | - Ranjit Sah
- Department of Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal
| | - Amro A. El-Sakka
- Faculty of Medicine, Suez Canal University, Ismailia 41511, Egypt
| | | | - Mrinmoy Kundu
- Institute of Medical Sciences and SUM Hospital, Siksha ‘O’ Anusandhan, Bhubaneswar 751003, India
| | - Fatma Labieb
- Faculty of Medicine, Beni-Suef Univesity, Beni-Suef 62511, Egypt
| | | | - Abdelaziz Abdelaal
- Harvard Medical School, Boston, MA 02115, USA
- Boston University, MA 02215, USA
- Tanta University Hospitals, 31516 Egypt
| | - Basel Abdelazeem
- Department of Internal Medicine, McLaren Health Care, Flint, Michigan 48532, USA
- Department of Internal Medicine, Michigan State University, East Lansing, Michigan 48823, USA
| | - D. Katterine Bonilla-Aldana
- Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Latin American Network on MOnkeypox VIrus research (LAMOVI), Pereira, Risaralda, Colombia
| | | | | | - Mohammed A. Garout
- Community Medicine and Pilgrims Health Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | - Darwin A. León-Figueroa
- Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Facultad de Medicina Humana, Universidad de San Martín de Porres, Chiclayo, Peru
- Emerge, Unidad de Investigación en Enfermedades Emergentes y Cambio Climático, Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Monica Pachar
- Medicine Department-Infectious Diseases Service, Hospital Santo Tomas, Panama City, Panama
| | - José Antonio Suárez
- Investigador SNI Senacyt Panamá, Clinical Research Deparment, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama
| | - Juan David Ramirez
- Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centro de Investigaciones en Microbiología y Biotecnología-UR (CIMBIUR), Facultad de Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia
| | - Alberto Paniz-Mondolfi
- Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ali A. Rabaan
- Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia
- College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia
- Department of Public Health and Nutrition, The University of Haripur, Haripur, 22610, Pakistan
| | - Jaffar A. Al-Tawfiq
- Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia
- Infectious Diseases Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
- Infectious Diseases Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Hiroshi Nishiura
- Kyoto University School of Public Health, Yoshidakonoecho, Sakyoku, Kyoto City 6068501, Japan
| | - Yeimer Ortiz-Martínez
- Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Department of Internal Medicine, Universidad Industrial de Santander, Bucaramanga, Santander, Colombia
| | | | - Sergio Cimerman
- Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil Brazilian Society for Infectious Diseases, São Paulo, SP, Brazil
| | - Alexandre Naime Barbosa
- Infectious Diseases Department, Botucatu Medical School, UNESP Brazilian Society for Infectious Diseases, São Paulo, SP, Brazil
| | - Pasquale Pagliano
- Department of Infectious Diseases, University of Salerno, Salerno, Italy
| | | | - Jaime A. Cardona-Ospina
- Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, 660003, Pereira, Risaralda, Colombia
| | - Beatrice Bížová
- Department of Dermatovenerology, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
| | - Alfonso J. Rodriguez-Morales
- Grupo de Investigación Biomedicina, Faculty of Medicine, Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Latin American Network on MOnkeypox VIrus research (LAMOVI), Pereira, Risaralda, Colombia
- Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia
- Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas, 660003, Pereira, Risaralda, Colombia
- Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, 4861, Peru
| |
Collapse
|
5
|
Abdelazeem B, Abbas KS, Labieb F, Arida AK, El-Shahat NA, Shehata J, Kandah E, Malik B, Akanbi M, Rafae A, Wahab A, Ehsan H. The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials. Expert Rev Anticancer Ther 2022; 22:1127-1140. [DOI: 10.1080/14737140.2022.2116005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Basel Abdelazeem
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | | | - Fatma Labieb
- Faculty of Medicine, Beni Suef University, , Beni Suef, Egypt, 62521
| | - Abdul Karim Arida
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | | | - Joseph Shehata
- Faculty of Medicine, Cairo University, Cairo, Egypt, 11562
| | - Emad Kandah
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | - Bilal Malik
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | - Maxwell Akanbi
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | - Abdul Rafae
- McLaren Health Care, Flint, Michigan, USA, 48532
- Michigan State University, East Lansing, Michigan, USA, 48824
| | - Ahsan Wahab
- Baptist Medical Center South/Prattville Baptist Hospital, Montgomery, Alabama, USA, 36067
| | - Hamid Ehsan
- Levine Cancer Institute, Charlotte, NC, USA, 28277
| |
Collapse
|
6
|
Abdelazeem B, Abbas KS, Labieb F, Arida AK, El-Shahat NA, Shehata J, Kandah E, Malik B, Akanbi MO, Rafae A, Tahir N, Wahab A, Ehsan H. Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for non-small cell lung cancer: A systematic review and meta-analysis. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.e21092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21092 Background: There is an emerging role of immunotherapy plus chemotherapy (ICC) in the front-line setting for the treatment of Non-Small Cell Lung Cancer (NSCLC) with reported improvement in overall survival (OS) and progression-free survival (PFS). In this review, we highlighted the efficacy and safety of combination regimens as a first-line therapy for NSCLC. Methods: A comprehensive literature search was done on PubMed, Cochrane, Embase, WOS, and Scopus until Dec-2021. The outcomes included progression free survival (PFS) and/or overall survival (OS) and treatment-related adverse events (TRAEs). The inverse variance method was used to generate hazard ratios (HR) with the corresponding 95% confidence intervals for the OS and PFS. Meanwhile, Mantle-Hazard variance was used to create risk ratios for TRAEs. Results: The total eleven randomized controlled trials (RCTs) involving 6,386 patients (pts) were included. 3,850 pts received ICC while 2536 pts received chemotherapy., Four studies each used atezolizumab and pembrolizumab while one study each used nivolumab, tislelizumab, and camrelizumab. The ICC group showed a significant improvement in both PFS (HR, 0.60; 95% CI, 0.54-0.66; p = < 0.00001) and OS (HR, 0.77; 95% CI, 0.68-0.87; p = < 0.0001). Atezolizumab combinations have better PFS and OS compared to the other combinations; HR 0.65 (0.59-0.71) and 0.82 (0.74-0.90), respectively. There was no statistically significant difference between the ICC and control groups regarding TRAEs (RR, 1.07; 95% CI, 0.99-1.16; p = 0.09). Further subgroup analysis is mentioned in the table. Conclusions: The ICC seems to be a promising front-line therapy for NSCLC with superior PFS and OS compared to chemotherapy alone and without significant increase in TRAES. [Table: see text]
Collapse
Affiliation(s)
| | | | - Fatma Labieb
- Faculty of Medicine, Beni Suef University, Beni Suef, Egypt
| | | | | | | | | | | | | | | | - Nayha Tahir
- Chicago Medical School, Rosalind Franklin University of Medicine and Science, Northwestern Hospital McHenry, Chicago, IL
| | - Ahsan Wahab
- Baptist Medical Center South/Prattville Baptist Hospital, Montgomery, AL
| | - Hamid Ehsan
- Levine Cancer Institute, Atrium Health, Charlotte, NC
| |
Collapse
|
7
|
Abdelazeem B, Abbas KS, Ahmad S, Raslan H, Labieb F, Savarapu P. The Effect of Angiotensin II Receptor Blockers in Patients with Hypertrophic Cardiomyopathy: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. Rev Cardiovasc Med 2022. [DOI: 10.31083/j.rcm2304141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|